Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca²⁺/CaN Signaling Pathway

Abstract

Astragaloside IV is widely used for the treatment of cardiovascular diseases in China. However, its role in cardiac hypertrophy remains unclear. In this study, we aim to determine the protective effects of astragaloside IV on myocardial hypertrophy induced by lipopolysaccharide and to identify their precise molecular and cellular mechanisms. Cell size, reorganization of actin filaments, and ANP and BNP mRNA expression were used as indices of hypertrophy; CaN and GATA-4 expression and the distribution of NFAT-3 in both cytoplasm and nucleus were determined by Western blot analysis; Ca²⁺ transient in Fura-2/AM-loaded cells was measured by Till image system. Our data demonstrated that lipopolysaccharide challenge induced cardiac hypertrophy, increased resting Ca²⁺ transient level, promoted activation of CaN and GATA-4, and enhanced nuclear translocation of NFAT-3. Administration of astragaloside IV (16, 32, and 64 µM) 1 h prior to lipopolysaccharide stimulation dose-dependently attenuated cardiac hypertrophy induced by lipopolysaccharide. Further studies demonstrated that astragaloside IV inhibited the increment of the resting intracellular free Ca²⁺, and its effect was similar to verapamil. Moreover, astragaloside IV also inhibited the activation of CaN and GATA-4, and the nuclear translocation of NFAT-3 induced by lipopolysaccharide. In conclusion, our results revealed that astragaloside IV had the potential to protect against cardiac hypertrophy through Ca²⁺-mediated CaN signaling pathways.

Key words

astragaloside IV - cardiac hypertrophy - calcium - calcineurin

• References

• 1 Li M, Yu L, She T, Gan Y, Liu F, Hu Z, Chen Y, Li S, Xia H. Astragaloside IV attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells. Eur J Pharmacol 2012; 696: 203-209
• 2 Yu J, Zhang Y, Sun S, Shen J, Qiu J, Yin X, Yin H, Jiang S. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol 2006; 84: 579-587
• 3 Chen X, Peng LH, Shan YH, Li N, Wei W, Yu L, Li QM, Liang WQ, Gao JQ. Astragaloside IV-loaded nanoparticle-enriched hydrogel induces wound healing and anti-scar activity through topical delivery. Int J Pharm 2013; 447: 171-181
• 4 Gao XH, Xu XX, Pan R, Li Y, Luo YB, Xia YF, Murata K, Matsuda H, Dai Y. Matsu-Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway. J Nat Med 2009; 63: 421-429
• 5 Qiu LH, Xie XJ, Zhang BQ. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull 2010; 33: 641-646
• 6 Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D. Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali . Biol Pharm Bull 2009; 32: 132-135
• 7 Li X, Wang X, Han C, Wang X, Xing G, Zhou L, Li G, Niu Y. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p 38 MAPK pathway. Free Radic Biol Med 2013; 60: 168-176
• 8 Chan WS, Durairajan SS, Lu JH, Wang Y, Xie LX, Kum WF, Koo I, Yung KK, Li M. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem Int 2009; 55: 414-422
• 9 Zhang WD, Chen H, Zhang C, Liu RH, Li HL, Chen HZ. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro . Planta Med 2006; 72: 4-8
• 10 Wu X, Cao Y, Nie J, Liu H, Lu S, Hu X, Zhu J, Zhao X, Chen J, Chen X, Yang Z, Li X. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol 2013; 182: 2005-2014
• 11 Zhao J, Yang P, Li F, Tao L, Ding H, Rui Y, Cao Z, Zhang W. Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis. PLoS One 2012; 7: e44938
• 12 Zhao M, Zhao J, He G, Sun X, Huang X, Hao L. Effects of astragaloside IV on action potentials and ionic currents in guinea-pig ventricular myocytes. Biol Pharm Bull 2013; 36: 515-521
• 13 Meng D, Chen XJ, Bian YY, Li P, Yang D, Zhang JN. Effect of astragalosides on intracellular calcium overload in cultured cardiac myocytes of neonatal rats. Am J Chin Med 2005; 33: 11-20
• 14 Xu XL, Ji H, Gu SY, Shao Q, Huang QJ, Cheng YP. Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo . Eur J Pharmacol 2007; 568: 203-212
• 15 Xu XL, Chen XJ, Ji H, Li P, Bian YY, Yang D, Xu JD, Bian ZP, Zhang JN. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology 2008; 81: 325-332
• 16 Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-10692
• 17 Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL, Godowski PJ. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395: 284-288
• 18 Liu CJ, Cheng YC, Lee KW, Hsu HH, Chu CH, Tsai FJ, Tsai CH, Chu CY, Liu JY, Kuo WW, Huang CY. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol Cell Biochem 2008; 313: 167-178
• 19 Singh MV, Swaminathan PD, Luczak ED, Kutschke W, Weiss RM, Anderson ME. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol 2012; 52: 1135-1144
• 20 Thompson M, Kliewer A, Maass D, Becker L, White DJ, Bryant D, Arteaga G, Horton J, Giroir BP. Increased cardiomyocyte intracellular calcium during endotoxin-induced cardiac dysfunction in guinea pigs. Pediatr Res 2000; 47: 669-676
• 21 Ren J, Avery J, Zhao H, Schneider JG, Ross FP, Muslin AJ. Beta3 Integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol 2007; 42: 367-377
• 22 Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 119-129
• 23 Saito T, Fukuzawa J, Osaki J, Sakuragi H, Yao N, Haneda T, Fujino T, Wakamiya N, Kikuchi K, Hasebe N. Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol 2003; 35: 1153-1160
• 24 Fu M, Zhang J, Xu S, Pang Y, Liu N, Tang C. Role of calcineurin in angiotensin II-induced cardiac myocyte hypertrophy of rats. Chin Med Sci J 2001; 16: 1-4
• 25 Lu CC, Xu YQ, Wu JC, Hang PZ, Wang Y, Wang C, Wu JW, Qi JC, Zhang Y, Du ZM. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 747-755
• 26 Zhu W, Zou Y, Shiojima I, Kudoh S, Aikawa R, Hayashi D, Mizukami M, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I. Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem 2000; 275: 15239-15245
• 27 Wang GJ, Wang HX, Yao YS, Guo LY, Liu P. The role of Ca2+/calmodulin-dependent protein kinase II and calcineurin in TNF-α-induced myocardial hypertrophy. Braz J Med Biol Res 2012; 45: 1045-1051
• 28 Wang HY, Liu XY, Han G, Wang ZY, Li XX, Jiang ZM, Jiang CM. LPS induces cardiomyocyte injury through calcium-sensing receptor. Mol Cell Biochem 2013; 379: 153-159
• 29 Zhang T, Lu X, Li J, Chidiac P, Sims SM, Feng Q. Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia. Basic Res Cardiol 2012; 107: 254
• 30 Suzuki J, Bayna E, Li HL, Molle ED, Lew WY. Lipopolysaccharide activates calcineurin in ventricular myocytes. J Am Coll Cardiol 2007; 49: 491-499
• 31 Yang J, Wang HD, Lu DX, Wang YP, Qi RB, Li J, Li F, Li CJ. Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF-α secretion, abnormal calcium cycling, and cardiac dysfunction in rats1. Acta Pharmacol Sin 2006; 27: 173-178
• 32 Xu XL, Ji H, Gu SY. Protective effects of astragaloside on isoproterenol induced cardiac hypertrophy in mice. J China Pharm Univ 2007; 38: 451-455
• 33 Wang J, Liu JH, Yao P. Protective effect of astragaloside IV on isoproterenol induced myocardial injury. J Shanghai Jiaotong Univ (Medical Science) 2007; 27: 384-386
• 34 Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W, Tang L. Effects of Astragaloside IV on heart failure in rats. Chin Med 2009; 4: 6
• 35 Wu X, Cao Y, Nie J, Liu H, Lu S, Hu X, Zhu J, Zhao X, Chen J, Chen X, Yang Z, Li X. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol 2013; 182: 2005-2014
• 36 Lu M, Wang H, Yang Y, Zhang L, Liu C, Yang J, Wong TM. The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of kappa-opioid receptor stimulation on myocardial hypertrophy induced by isoprenaline. Pharmazie 2012; 67: 182-186